Acute Myeloid Leukemia Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Summary
This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical stage pipeline products, with a launch date assessment by market for acute myeloid leukemia (AML). In addition to PBF sales data for the 8MM, this report contains sales forecast extrapolations for an additional 7 geographical markets (7M), totaling 15 markets (15M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.
The report also analyzes the clinical and commercial landscapes of AML, with pricing assumptions based on currently marketed products by class of cell therapies, accompanied by a transparent forecast methodology.
Additionally, the report evaluates indication-specific unmet needs and competitive assessment, and identifies key future players in the cell therapy market.
Synopsis
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook